Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Phillips

Urology Austin, TX Medical Doctor

NPI 1871546283 CMS profile 311299

608 Radam Ln, Austin, TX 78745

Open in the dashboard

General payments

$11,781

511 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Phillips of Austin, TX is reported in the CMS Open Payments database as having received $11,781 across 511 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $916 47
2024 General $1,378 66
2023 General $1,786 65
2022 General $1,733 84
2021 General $1,496 78
2020 General $2,856 63
2019 General $1,616 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Phillips
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Phillips were reported at $916. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Phillips Urology median Middle half National median
2019 $1,616 $480 $147–$1,201 $163
2020 $2,856 $246 $87–$645 $114
2021 $1,496 $358 $111–$1,000 $132
2022 $1,733 $476 $143–$1,263 $149
2023 $1,786 $560 $168–$1,461 $160
2024 $1,378 $563 $170–$1,464 $164
2025 $916 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dendreon Pharmaceuticals LLC $2,263 22 payments
  2. Janssen Biotech, Inc. $1,671 73 payments
  3. Pfizer Inc. $1,344 92 payments
  4. AbbVie, Inc. $1,269 61 payments
  5. Astellas Pharma US Inc $923 47 payments
  6. Boston Scientific Corporation $408 17 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $296 16 payments
  8. Blue Earth Diagnostics Limited $291 8 payments
  9. Sumitomo Pharma America, Inc. $248 13 payments
  10. Endo Pharmaceuticals Inc. $248 18 payments
  11. Other $2,822 144 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,679 499 payments
  2. Consulting Fee $1,690 1 payment
  3. Education $413 11 payments
Products named General payments · program years 2019–2025
  1. PROVENGE $2,263 22 payments
  2. XTANDI $1,935 122 payments
  3. ERLEADA $1,563 69 payments
  4. ORGOVYX Oncology $701 40 payments
  5. BOTOX $642 29 payments
  6. LUPRON DEPOT $455 23 payments
  7. TALZENNA $334 18 payments
  8. ORGOVYX Hormone Therapy $286 14 payments
  9. XIAFLEX $262 19 payments
  10. Nubeqa $249 13 payments
  11. Other $5,566 333 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

5,605

Median for Urology: 1,053

Drug cost

$7,683,436

Median for Urology: $101,464

Branded share of claims

36%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 262 $3,530,172
Orgovyx Relugolix Brand 587 $1,618,724
Nubeqa Darolutamide Brand 74 $951,459
Abiraterone Acetate Generic 326 $705,953
Xtandi Enzalutamide Brand 34 $370,287
Myrbetriq Mirabegron Brand 381 $246,993
Gemtesa Vibegron Brand 153 $103,045
Mirabegron Er Mirabegron Brand 71 $47,312
Tamsulosin Hcl Generic 1,031 $16,508
Jatenzo Testosterone Undecanoate Brand 19 $15,187

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$463,751

Of which drugs: $252,048

Medicare patients

854

Average age 76

Services billed

18,734

89 women, 765 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Ischemic heart disease 43%
Cancer 39%
Arthritis 38%
Diabetes 28%
Atrial fibrillation 24%
Chronic kidney disease 21%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 38 9,960 $203,113
Leuprolide injectable, camcevi, 1 mg J1952 Office 13 546 $23,585
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 19 120 $17,053

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $283
$283 262 —
BOTOX
  • AbbVie, Inc. $260
$260 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $92
  • PFIZER INC. $50
$142 587 —
XTANDI
  • Astellas Pharma US Inc $69
  • PFIZER INC. $50
$118 34 —
LYNPARZA
  • Merck Sharp & Dohme Corporation $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

511 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record